Rondo Therapeutics begins dosing in Phase I/Ib trial for solid tumours
The RNDO-564 trial is designed to address limitations of Nectin-4–targeting ADCs.
Clinical Trials
FDA clears VectorY’s PIONEER-ALS Phase I/II trial for ALS
PolarityBio concludes SkinTE’s Phase III trial for diabetic foot ulcers
Vandria announces topline results from Phase I trial of VNA-318
AbbVie reports Phase III study results of atogepant
IDEAYA receives FDA approval to begin IDE034 clinical trial
Imugene announces Phase Ib azer-cel efficacy data
Zuellig Pharma launches clinical trial facility in South Korea
